Researchers Set to Launch Phase 3 Trial for Parkinson's

The article describes the planned STEADY-PD3 Phase 3 clinical trial, which will evaluate whether isradipine can slow the progression of Parkinson’s disease. Supported by a $23 million NIH grant, the study planned to enroll 336 patients across 56 sites in North America and follow them for three years. Importantly, Carematix will support the trial’s operations, including data management and real-time transmission of patients’ blood-pressure readings from their homes to researchers. Readers will gain insight into how remote patient monitoring and connected medical devices can support clinical trials, allowing researchers to collect patient data remotely and securely. The article also demonstrates how Carematix’s technology can contribute to decentralized clinical research, real-time data collection, and more efficient clinical trial operations.